Pi2 Solutions introduces 2010 version of Product Literature Database System

NewsGuard 100/100 Score

Pi2 Solutions announces the all-new 2010 version of their world-leading Product Literature Database System. This versatile application builds on the success of the 2003 version in use in biopharmaceutical companies around the globe.

In addition to the well-appreciated Guided, Advanced, Author and Thesaurus search interfaces, the new version introduces a number of unique features to aid users of product related information:

- Customisable Homepages: client administrators can set up multiple homepages so users in different pharma regions or therapeutic categories can use quick links to access specifically relevant content. Users can also configure a personal homepage using drag & drop - Variable user rights: different user groups can have restricted views on content - Current awareness: clickable email alerts for individuals or groups, daily, weekly, etc - Multiple indexes per article, each index specific to one drug allowing pinpoint association of, for example, AE or dosage information, with a specific drug - Links to full-article versions, according to subscriptions, and to various "Related Resources" that cite the literature, such as medical letters, monographs and much more - Study-specific indexing so that all publications from a given study can be quickly recognised and the resulting documentation readily downloaded - Ability to effortlessly download a Related Resource, its relevant bibliographic records and all associated full-articles and other PDFs - Complete intra-operability with Pi2's pipeline of downstream workflow tools, eg. Pi2's forthcoming software for handling submissions reference requests, creating and managing medical letters, the Pi2 KOL Db and Pi2 TrialWatch. - A new "Copy link" feature which enables pinpoint linking into a client's PLD from other client systems and documents. - Enhanced custom thesaurus handling capabilities - High performance and scalability to >1 million records

The roll-out of the Pi2 2010 PLD version to current clients will be completed in Q2 and new clients will automatically get the upgraded system. Demonstrations to prospective clients will feature the new system together with compatible Pi2 pipeline applications to assist users in their day to day workflow.

Pi2 Product Literature Database (PLD) Systems and Downstream Workflow Applications

Pi2 PLD systems track journal and conference articles that mention a client's drugs and, optionally, those of their competitors. Database records link to the full text articles, to various Related Resources that cite the literature and integrate with a variety of client end-user systems. They typically drive efficiency in an organisation, have a very low ownership cost and generally save a client company many times what they would spend on acquiring a Pi2 PLD. Pi2 PLD systems are widely regarded as being unrivalled in terms of functionality, ease of use and low burden of ownership. Pi2's "Downstream Workflow Applications" will increasingly enable end-users to create and manage their medical letters, create publications planning reports, organise KOLs, as well as tracking clinical trials and medical conferences. Seamless linking between the various Pi2 applications and integration with client internal systems ensure efficiency, greater workflow effectiveness and ease of working.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood